Kings Research today announced the release of its latest market intelligence study, “Global Inhalable Biologics Market: Size, Share, Trends & Forecast 2024–2031.” The report provides a comprehensive analysis of the market’s trajectory, including forecasts, drivers, opportunities, and competitive dynamics.
According to Kings Research, the global inhalable biologics market was valued at USD 3,210.0 million in 2023 and is projected to grow to USD 10,844.5 million by 2031, at a CAGR of 16.56% during 2024–2031. This growth is driven by the increasing prevalence of respiratory diseases and a rising preference for non-invasive drug delivery methods.
Inhalable biologics encompass biologic drugs administered through the lungs, including proteins, antibodies, and vaccines. These therapies offer targeted delivery, faster onset of action, and improved patient adherence compared to traditional injectable biologics. The market is experiencing significant growth due to advancements in inhalation technology and a shift towards self-administered treatments.
Recent clinical trials highlight the progress and potential of inhalable biologics. A 48‑week placebo‑controlled trial is evaluating the efficacy of inhaled molgramostim for respiratory diseases (Source: https://clinicaltrials.gov/). Another 52‑week study is examining the safety and efficacy of GB0139, a galectin‑3 inhibitor administered via dry powder inhalation (Source https://clinicaltrials.gov/). Additionally, a Phase 2b/3 trial is assessing the effects of AV‑101 (dry powder inhaled imatinib) for pulmonary arterial hypertension (https://clinicaltrials.gov/).
These studies underline the growing focus on inhalable biologics as a promising therapeutic approach, driven by both technological innovation and robust clinical evidence.
Kings Research identifies the following growth accelerators:
- Advancements in Dry Powder Inhalers (DPIs): Innovations in DPI technology are enhancing the stability and delivery efficiency of inhalable biologics, making them more effective and patient-friendly.
- Peptide-Based Therapies: The development of peptide-based inhalable biologics is expanding treatment options for various diseases, including diabetes and respiratory conditions.
- Self-Administration Trends: Patients' increasing preference for self-administered therapies is driving demand for inhalable biologics, offering convenience and autonomy in treatment. Studies show that examine the self-administration of biologics in asthma treatment, noting that most patients (≥89%) in two phase 3 studies reported completing self-administration easily without repeated reference to instructions (Source: https://pmc.ncbi.nlm.nih.gov/).
- Rising Respiratory Disease Prevalence: The global increase in respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), is fueling the demand for effective inhalable treatments.
- Technological Advancements: Continuous improvements in inhalation devices and formulation technologies are enhancing the efficacy and patient compliance of inhalable biologics.
For decision makers—CIOs, CTOs, COOs—the inhalable biologics market offers:
- Efficiency: Faster workflows and shorter treatment times.
- Cost Savings: Fewer hospital visits and healthcare resource utilization.
- Scalability & Agility: Scalable and agile treatment solutions across geographies.
- Compliance & Risk Mitigation: Better patient adherence and monitoring.
- Innovation & Experience: Innovation and better patient and provider experience.
Regional Outlook
- North America: Leads the market with 37.47% share in 2023, valued at USD 1,202.7 million. Advanced healthcare infrastructure and high biologics adoption in the region are the reasons.
- Asia-Pacific: Will grow fastest, driven by increasing healthcare access, rising respiratory disease prevalence, and the growing pharma industry in countries like India and China.
Competitive Landscape
Prominent companies are expanding via acquisitions, partnerships, and product launches. Key market players include AstraZeneca, MannKind Corporation, Synairgen plc., Pulmocide, Aerogen Ltd, Liquidia Corporation, Nephron Pharmaceuticals Corporation, InCarda Therapeutics, Inc., Agomab Therapeutics, Acu-Flow Limited, ReCode Therapeutics, AATec Medical GmbH, Avalyn Pharma Inc., VERO Biotech, and Spexis Ltd.
The full Kings Research report provides detailed segmentation by product type, indication, delivery device, distribution channel, and geography. To request a sample, access the full report, or explore custom consulting services, please visit https://www.kingsresearch.com/inhalable-biologics-market-1690.
About Kings Research
Kings Research is a global provider of syndicated research reports and consulting services, helping organizations navigate emerging markets, assess opportunities, and make informed business decisions.
All market data are sourced from Kings Research proprietary analysis, validated against public releases and credible industry sources. Sources include ClinicalTrials.gov and NCBI.